Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Roche Holding AG

Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competitive market landscape, potentially outperforming Wegovy in efficacy. The race to redefine obesity treatment is heating up, with several other pharmaceutical companies developing GLP-1 agonists and exploring alternative targets.

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

NVIDIA

Taiwan Semiconductor Manufacturing

The extraordinary rise of Nvidia (NASDAQ: NVDA ) was driven by the emergence of generative AI. This technology hinges on the use of powerful computer chips in which the stock is a market leader.

The $1 Trillion Question: Will LLY, TSMC or TSLA Be Wall Street's Next Nvidia?

Vertex Pharmaceuticals

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Sales of new highly effective weight management treatments are soaring. Eli Lilly entered the weight management arena after its main rival, Novo Nordisk, but clinical trial results suggest its drug could become the market leader.

Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?

There are only six trillion-dollar stocks worldwide, every one of which is a popular name. And they all rightfully sit at the top of their sectors.

The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone

Eli Lilly is facing a major delay with its latest Alzheimer's program. Regulators are bringing in outside experts to review its approval request.

Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?

Amazon

Eli Lilly recently selected Amazon Pharmacy to fill online prescriptions for its LillyDirect platform. This partnership benefits both Lilly and Amazon.

Eli Lilly Partners With Amazon's Pharmacy Business: Here's Why Both Stocks Should Win From the Deal

Eli Lilly's powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk's rival obesity medicine Wegovy for the first time since it was launched, according to data from IQVIA.

Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time

Eli Lilly has a huge opportunity in the anti-obesity market to generate tens of billions in revenue. The big battle could be over which company develops the best weight-loss drug.

Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.

Global X Health & Wellness Thematic ETF

When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.

3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold

Broadcom

Visa

Tesla has fallen behind six other companies in terms of market cap. These alternatives dominate industries, including weight management, payments, and semiconductors.

Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"

Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.

Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound

Cava Group, Inc.

Celsius Holdings

CrowdStrike

Dell Technologies

SoundHound AI Inc

Uber

If you want to know which growth stocks to sell this month, you're in the right place. Growth stocks have had a tremendous start to 2024.

7 Growth Stocks to Sell in March Before They Crash & Burn

Eli Lilly's potential approval for an Alzheimer's disease therapy is being delayed again. But even if the company doesn't earn this approval, it won't be the end of the world.

Should Investors Worry About Eli Lilly's Latest Regulatory Setback?

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Drugmaker Eli Lilly has teamed with Amazon to deliver medications to patients' homes. The partnership, announced Wednesday (March 13), will see Amazon Pharmacy serve as a third-party dispensing partner for LillyDirect, the company's new healthcare platform for patients being treated for diabetes, migraines or obesity.

Lilly Picks Amazon Pharmacy to Dispense Diabetes and Obesity Meds

Eli Lilly (LLY) and Amazon (AMZN) announced a partnership Wednesday that will allow Eli Lilly prescription drugs to be shipped through Amazon's online pharmacy, as Eli Lilly looks to expand its direct-to-consumer (DTC) business and Amazon expands its reach into the healthcare industry.

Eli Lilly, Amazon Partner for Direct-to-Consumer Delivery of Zepbound, Other Drugs

Eli Lilly And Co   (NYSE:LLY) today announced a new partnership with Amazon.com's  (AMZN) pharmacy to deliver drugs ordered via its LillyDirect service, including weight loss medication Zepbound, straight to consumers.

Eli Lilly Picks Amazon as Drug Delivery Partner

Netflix

The "Magnificent Seven" have produced impressive results in the past 10 years. Corporate giants Eli Lilly and Netflix have achieved similar returns over that time.

2 No-Brainer Stocks I'd Add to the "Magnificent Seven"

Eli Lilly (NYSE: LLY ) stock is in the news Wednesday after the company reached an agreement to sell its weight loss drug through Amazon (NASDAQ: AMZN )! This partnership has Amazon Pharmacy fulfilling direct orders for Eli Lilly made through its LillyDirect platform.

LLY Stock Alert: You Can Now Get Eli Lilly's Weight Loss Drugs on Amazon

Eli Lilly & Co. has tapped Amazon.com Inc.'s Amazon Pharmacy to provide home delivery of certain Lilly medicines, including obesity drug Zepbound, the companies said Wednesday.

Eli Lilly strikes deal with Amazon Pharmacy for home delivery of Zepbound, other drugs

The pharmaceutical giant has teamed up with Amazon Pharmacy to offer home delivery of certain medications through its drug-access platform.

Amazon Will Now Deliver Eli Lilly Weight Loss Drug

Hims & Hers Health

LifeMD 

Teladoc

Weightwatchers International Inc.

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

Eli Lilly said on Wednesday it has brought on Amazon.com's pharmacy unit to deliver drug prescriptions sent to its direct-to-consumer service, LillyDirect.

Lilly partners with Amazon to deliver Zepbound and other drugs

Amazon Pharmacy second online pharmacy to partner with Eli Lilly's site, and could provide faster deliveries for certain patients.

News for Eli Lilly Stock (LLY)